International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
-
Int. J. Gynecol. Cancer · Feb 2012
Meta AnalysisTumor necrosis factor α -308 G>A polymorphisms and cervical cancer risk: a meta-analysis.
Tumor necrosis factor α (TNF-α), secreted mainly by activated macrophages, is recently involved in fighting against tumorigenesis. Tumor necrosis factor α -308 G>A, the common polymorphism in the promoter of TNF-α, has been implicated to alter the risk of cervical cancer, yet the results of relative studies are inconclusive or controversial. To derive a more precise estimation of the relationship, we performed a meta-analysis based on 8 studies. ⋯ The natural genetic polymorphism in TNF-α -308 G>A is a risk factor for developing cervical cancer, especially for Asians and whites.
-
Int. J. Gynecol. Cancer · Feb 2012
Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Three large randomized clinical trials have shown a survival benefit for patients treated with intraperitoneal (IP) compared with intravenous chemotherapy for advanced stage epithelial ovarian cancer (EOC). However, the use of IP chemotherapy in recurrent EOC is controversial. The purpose of this study was to determine outcomes, completion rates, and frequency of complications in patients with platinum-sensitive recurrent EOC treated with IP chemotherapy. ⋯ Intraperitoneal chemotherapy is a feasible option for patients with recurrent EOC, with high completion rates, low frequency of complications, and acceptable PFS and OS.